Novel mechanism of rapamycin in GVHD: Increase in interstitial regulatory T cells

Jeanne Palmer, B. J. Chen, D. Deoliveira, N. D. Le, N. J. Chao

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Rapamycin (RAPA) is an immunosuppressive drug that prevents and treats graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplant (HCT). One possible mechanism for its efficacy is induction of tolerance, through increased number or enhanced survival of regulatory T cells. In our experiments, B10.D2 BM and splenocytes were injected into lethally irradiated BALB/cJ recipients. The mice received i.p. injections of either RAPA or vehicle control on days 1-28. There was a significant survival advantage in RAPA-treated mice. Evaluation of the skin biopsies showed a dense cellular infiltrate in RAPA-treated mice. Further characterization of these cells revealed a higher percentage of regulatory T cells characterized by FoxP3-positive cells in high-dose RAPA-treated mice as compared with controls on day 30. This effect appears to be dose dependent. When peripheral blood analysis for FoxP3-positive cells was performed, there was no significant difference observed in the RAPA-treated mice as compared with control mice. These data show a novel mechanism of rapamycin in GVHD, accumulation of regulatory T cells in the GVHD target tissue: the skin.

Original languageEnglish (US)
Pages (from-to)379-384
Number of pages6
JournalBone Marrow Transplantation
Volume45
Issue number2
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Fingerprint

Graft vs Host Disease
Regulatory T-Lymphocytes
Sirolimus
Skin
Immunosuppressive Agents
Transplants
Biopsy
Injections
Pharmaceutical Preparations

Keywords

  • Graft-versushost disease
  • Rapamycin
  • Regulatory T cells

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Novel mechanism of rapamycin in GVHD : Increase in interstitial regulatory T cells. / Palmer, Jeanne; Chen, B. J.; Deoliveira, D.; Le, N. D.; Chao, N. J.

In: Bone Marrow Transplantation, Vol. 45, No. 2, 01.02.2010, p. 379-384.

Research output: Contribution to journalArticle

Palmer, Jeanne ; Chen, B. J. ; Deoliveira, D. ; Le, N. D. ; Chao, N. J. / Novel mechanism of rapamycin in GVHD : Increase in interstitial regulatory T cells. In: Bone Marrow Transplantation. 2010 ; Vol. 45, No. 2. pp. 379-384.
@article{e4b6d72a2e8744ffb4f8bc3952f17f2e,
title = "Novel mechanism of rapamycin in GVHD: Increase in interstitial regulatory T cells",
abstract = "Rapamycin (RAPA) is an immunosuppressive drug that prevents and treats graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplant (HCT). One possible mechanism for its efficacy is induction of tolerance, through increased number or enhanced survival of regulatory T cells. In our experiments, B10.D2 BM and splenocytes were injected into lethally irradiated BALB/cJ recipients. The mice received i.p. injections of either RAPA or vehicle control on days 1-28. There was a significant survival advantage in RAPA-treated mice. Evaluation of the skin biopsies showed a dense cellular infiltrate in RAPA-treated mice. Further characterization of these cells revealed a higher percentage of regulatory T cells characterized by FoxP3-positive cells in high-dose RAPA-treated mice as compared with controls on day 30. This effect appears to be dose dependent. When peripheral blood analysis for FoxP3-positive cells was performed, there was no significant difference observed in the RAPA-treated mice as compared with control mice. These data show a novel mechanism of rapamycin in GVHD, accumulation of regulatory T cells in the GVHD target tissue: the skin.",
keywords = "Graft-versushost disease, Rapamycin, Regulatory T cells",
author = "Jeanne Palmer and Chen, {B. J.} and D. Deoliveira and Le, {N. D.} and Chao, {N. J.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1038/bmt.2009.140",
language = "English (US)",
volume = "45",
pages = "379--384",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Novel mechanism of rapamycin in GVHD

T2 - Increase in interstitial regulatory T cells

AU - Palmer, Jeanne

AU - Chen, B. J.

AU - Deoliveira, D.

AU - Le, N. D.

AU - Chao, N. J.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Rapamycin (RAPA) is an immunosuppressive drug that prevents and treats graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplant (HCT). One possible mechanism for its efficacy is induction of tolerance, through increased number or enhanced survival of regulatory T cells. In our experiments, B10.D2 BM and splenocytes were injected into lethally irradiated BALB/cJ recipients. The mice received i.p. injections of either RAPA or vehicle control on days 1-28. There was a significant survival advantage in RAPA-treated mice. Evaluation of the skin biopsies showed a dense cellular infiltrate in RAPA-treated mice. Further characterization of these cells revealed a higher percentage of regulatory T cells characterized by FoxP3-positive cells in high-dose RAPA-treated mice as compared with controls on day 30. This effect appears to be dose dependent. When peripheral blood analysis for FoxP3-positive cells was performed, there was no significant difference observed in the RAPA-treated mice as compared with control mice. These data show a novel mechanism of rapamycin in GVHD, accumulation of regulatory T cells in the GVHD target tissue: the skin.

AB - Rapamycin (RAPA) is an immunosuppressive drug that prevents and treats graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplant (HCT). One possible mechanism for its efficacy is induction of tolerance, through increased number or enhanced survival of regulatory T cells. In our experiments, B10.D2 BM and splenocytes were injected into lethally irradiated BALB/cJ recipients. The mice received i.p. injections of either RAPA or vehicle control on days 1-28. There was a significant survival advantage in RAPA-treated mice. Evaluation of the skin biopsies showed a dense cellular infiltrate in RAPA-treated mice. Further characterization of these cells revealed a higher percentage of regulatory T cells characterized by FoxP3-positive cells in high-dose RAPA-treated mice as compared with controls on day 30. This effect appears to be dose dependent. When peripheral blood analysis for FoxP3-positive cells was performed, there was no significant difference observed in the RAPA-treated mice as compared with control mice. These data show a novel mechanism of rapamycin in GVHD, accumulation of regulatory T cells in the GVHD target tissue: the skin.

KW - Graft-versushost disease

KW - Rapamycin

KW - Regulatory T cells

UR - http://www.scopus.com/inward/record.url?scp=76749087402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749087402&partnerID=8YFLogxK

U2 - 10.1038/bmt.2009.140

DO - 10.1038/bmt.2009.140

M3 - Article

C2 - 19597415

AN - SCOPUS:76749087402

VL - 45

SP - 379

EP - 384

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -